Along with resolving site inspection issues that cost Regeneron a high-dose Eylea launch in June, the company has scored an FDA nod for Veopoz as the first treatment for the ultra-rare inherited ...

Regeneron Pharmaceuticals (REGN.O), opens new tab said on Friday the U.S. health regulator approved its drug to treat a rare blood disease. The drug pozelimab, branded as Veopoz, would treat ...

According to a Regeneron press release, Veopoz (pozelimab-bbfg, Regeneron) is a fully human, monoclonal antibody designed to target complement factor C5, a protein involved in the activation of ...

The FDA approved Regeneron Pharmaceuticals Inc's REGN Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient protein ...

Regeneron scored a pair of key regulatory approvals from the Food and Drug Administration late last week. On Friday, the FDA approved Veopoz, a subcutaneous injection, for treating adults and ...

Credit: Regeneron. Veopoz is supplied as a 400mg/2mL solution in a single-dose vial. The Food and Drug Administration (FDA) has approved Veopoz ™ (pozelimab-bbfg) for the treatment of adult and ...

Earlier in the day, the FDA approved another Regeneron drug, branded as Veopoz to treat a rare blood disease CHAPLE. With Veopoz's approval, the company said earlier that the pre-approval ...

Regeneron pulled off a rare double play on Friday afternoon as it scored two FDA approvals—one under the radar and the other highly anticipated. After the FDA signed off on Veopoz to treat ultra ...

Inc. ("Regeneron") has chosen Orsini to be the exclusive specialty pharmacy partner for VEOPOZ™ (pozelimab-bbfg). A monoclonal antibody, VEOPOZ is the first and only treatment for those living ...